Destin A. Leblanc
Cleaning Validation (eBook, PDF)
Practical Compliance Approaches for Pharmaceutical Manufacturing
26,95 €
26,95 €
inkl. MwSt.
Sofort per Download lieferbar
13 °P sammeln
26,95 €
Als Download kaufen
26,95 €
inkl. MwSt.
Sofort per Download lieferbar
13 °P sammeln
Jetzt verschenken
Alle Infos zum eBook verschenken
26,95 €
inkl. MwSt.
Sofort per Download lieferbar
Alle Infos zum eBook verschenken
13 °P sammeln
Destin A. Leblanc
Cleaning Validation (eBook, PDF)
Practical Compliance Approaches for Pharmaceutical Manufacturing
- Format: PDF
- Merkliste
- Auf die Merkliste
- Bewerten Bewerten
- Teilen
- Produkt teilen
- Produkterinnerung
- Produkterinnerung
Bitte loggen Sie sich zunächst in Ihr Kundenkonto ein oder registrieren Sie sich bei
bücher.de, um das eBook-Abo tolino select nutzen zu können.
Hier können Sie sich einloggen
Hier können Sie sich einloggen
Sie sind bereits eingeloggt. Klicken Sie auf 2. tolino select Abo, um fortzufahren.
Bitte loggen Sie sich zunächst in Ihr Kundenkonto ein oder registrieren Sie sich bei bücher.de, um das eBook-Abo tolino select nutzen zu können.
Pharmaceutical manufacturers and upper management are encouraged to meet the challenges of the science-based and risk-based approaches to cleaning validation. Using some of the principles and practices in this Volume will help in designing a more effective and efficient cleaning validation program.
- Geräte: PC
- ohne Kopierschutz
- eBook Hilfe
- Größe: 1.87MB
Andere Kunden interessierten sich auch für
- Destin A. LeblancCleaning Validation (eBook, ePUB)26,95 €
- High-Throughput Lead Optimization in Drug Discovery (eBook, PDF)65,95 €
- Biointeractions of Nanomaterials (eBook, PDF)148,95 €
- Marine Surfactants (eBook, PDF)62,95 €
- Christophe WiartHandbook of Medicinal Plants of the World for Aging (eBook, PDF)52,95 €
- Textbook of Ion Channels Volume III (eBook, PDF)96,95 €
- Sunil KaulAshwagandha for Quality of Life (eBook, PDF)52,95 €
-
-
-
Pharmaceutical manufacturers and upper management are encouraged to meet the challenges of the science-based and risk-based approaches to cleaning validation. Using some of the principles and practices in this Volume will help in designing a more effective and efficient cleaning validation program.
Dieser Download kann aus rechtlichen Gründen nur mit Rechnungsadresse in A, B, BG, CY, CZ, D, DK, EW, E, FIN, F, GR, HR, H, IRL, I, LT, L, LR, M, NL, PL, P, R, S, SLO, SK ausgeliefert werden.
Produktdetails
- Produktdetails
- Verlag: Taylor & Francis
- Seitenzahl: 216
- Erscheinungstermin: 23. Dezember 2022
- Englisch
- ISBN-13: 9781000835595
- Artikelnr.: 66716201
- Verlag: Taylor & Francis
- Seitenzahl: 216
- Erscheinungstermin: 23. Dezember 2022
- Englisch
- ISBN-13: 9781000835595
- Artikelnr.: 66716201
- Herstellerkennzeichnung Die Herstellerinformationen sind derzeit nicht verfügbar.
Destin LeBlanc is a consultant at Cleaning Validation Technologies. He has extensive experience in product development and technical services for cleaning and antimicrobial applications. He is an international lecturer on contamination control and has written widely on cleaning validation topics including four volumes in the "Cleaning Validation: Practical Compliance Solutions for Pharmaceutical Manufacturing" series published by PDA and DHI. He is a member of PDA and ISPE and has trained FDA personnel on cleaning validation. He is a graduate of the University of Michigan and the University of Iowa.
Terminology
1. Use of the Term "Product"
2. Use of the Terms Grouping and Matrixing
3. Deviations and Nonconformances
4. Clarifying Terms: Blanks vs. Controls
5. Meaning of "Dedicated"?
6. Words (Again??)
Health-based Limits
7. What's at Stake with HBELs
8. A Look at the Revised Risk-MaPP
9. EMA's Q&A Clarification: Part 1
10. EMA's Q&A Clarification: Part 2
11. The EMA Q&A "Clarification" on Limits
12. The EMA Q&A on Routine Analytical Testing
13. Other Issues in EMA's Q&A
14. Highly Hazardous Products in Shared Facilities
Limits - General
15. EMA vs. ISPE on Cleaning Limits?
16. Does a High "Margin of Safety" Protect Patients?
17. What If the Next Product is the Same Product?
18. Limits for "Product A to Product A"
19. Surfaces Areas in Carryover Calculations
20. Carryover Calculation Errors to Avoid
21. Protocol Limits for Yeasts/Molds?
22. Cleaning Validation for Homeopathic Drug Products
23. A Possible Approach for Biotech Limits
24. Establishing Clearance for Degraded Protein Actives
Visually Clean
25. Avoiding "Visually Dirty" Observations
26. What's a Visual Limit?
27. Visual Residue Limits - Part 1
28. Visual Residue Limits - Part 2
Analytical and Sampling Methods
29. Two More Nails in the Coffin?
30. More Swab Sampling Issues
31. Timing for Swab Sampling in a Protocol?
32. Pass/Fail Analytical Test Methods
Product Grouping
33. Issues in Product Grouping
34. Toxicity as a Worst-Case Grouping Factor
35. Another "Worst Case" Product Grouping Idea
Protocols and Procedures
36. Issues in Rinsing - Part 1
37. Issues in Rinsing - Part 2
38. Routine Monitoring for Highly Hazardous Products
39. "Concurrent Release" for Cleaning Validation
40. Dirty and Clean Hold Time Protocols
API Manufacture
41. A Critique of the APIC Guideline
42. Another Issue for API Synthesis
43. Contaminants in API Manufacture
Miscellaneous
44. Significant Figures: Back to Basics
45. The Value of a Protocol Worksheet for Manual Cleaning
46. Dealing with Used and New Equipment
47. Solving Cleaning Validation Problems by Analogy
48. Causing Cleaning Validation Problems by Analogy
Appendix A: Acronyms Used in this Volume
Appendix B: Shorthand Notations for Expressing Limits
Index
1. Use of the Term "Product"
2. Use of the Terms Grouping and Matrixing
3. Deviations and Nonconformances
4. Clarifying Terms: Blanks vs. Controls
5. Meaning of "Dedicated"?
6. Words (Again??)
Health-based Limits
7. What's at Stake with HBELs
8. A Look at the Revised Risk-MaPP
9. EMA's Q&A Clarification: Part 1
10. EMA's Q&A Clarification: Part 2
11. The EMA Q&A "Clarification" on Limits
12. The EMA Q&A on Routine Analytical Testing
13. Other Issues in EMA's Q&A
14. Highly Hazardous Products in Shared Facilities
Limits - General
15. EMA vs. ISPE on Cleaning Limits?
16. Does a High "Margin of Safety" Protect Patients?
17. What If the Next Product is the Same Product?
18. Limits for "Product A to Product A"
19. Surfaces Areas in Carryover Calculations
20. Carryover Calculation Errors to Avoid
21. Protocol Limits for Yeasts/Molds?
22. Cleaning Validation for Homeopathic Drug Products
23. A Possible Approach for Biotech Limits
24. Establishing Clearance for Degraded Protein Actives
Visually Clean
25. Avoiding "Visually Dirty" Observations
26. What's a Visual Limit?
27. Visual Residue Limits - Part 1
28. Visual Residue Limits - Part 2
Analytical and Sampling Methods
29. Two More Nails in the Coffin?
30. More Swab Sampling Issues
31. Timing for Swab Sampling in a Protocol?
32. Pass/Fail Analytical Test Methods
Product Grouping
33. Issues in Product Grouping
34. Toxicity as a Worst-Case Grouping Factor
35. Another "Worst Case" Product Grouping Idea
Protocols and Procedures
36. Issues in Rinsing - Part 1
37. Issues in Rinsing - Part 2
38. Routine Monitoring for Highly Hazardous Products
39. "Concurrent Release" for Cleaning Validation
40. Dirty and Clean Hold Time Protocols
API Manufacture
41. A Critique of the APIC Guideline
42. Another Issue for API Synthesis
43. Contaminants in API Manufacture
Miscellaneous
44. Significant Figures: Back to Basics
45. The Value of a Protocol Worksheet for Manual Cleaning
46. Dealing with Used and New Equipment
47. Solving Cleaning Validation Problems by Analogy
48. Causing Cleaning Validation Problems by Analogy
Appendix A: Acronyms Used in this Volume
Appendix B: Shorthand Notations for Expressing Limits
Index
Terminology
1. Use of the Term "Product"
2. Use of the Terms Grouping and Matrixing
3. Deviations and Nonconformances
4. Clarifying Terms: Blanks vs. Controls
5. Meaning of "Dedicated"?
6. Words (Again??)
Health-based Limits
7. What's at Stake with HBELs
8. A Look at the Revised Risk-MaPP
9. EMA's Q&A Clarification: Part 1
10. EMA's Q&A Clarification: Part 2
11. The EMA Q&A "Clarification" on Limits
12. The EMA Q&A on Routine Analytical Testing
13. Other Issues in EMA's Q&A
14. Highly Hazardous Products in Shared Facilities
Limits - General
15. EMA vs. ISPE on Cleaning Limits?
16. Does a High "Margin of Safety" Protect Patients?
17. What If the Next Product is the Same Product?
18. Limits for "Product A to Product A"
19. Surfaces Areas in Carryover Calculations
20. Carryover Calculation Errors to Avoid
21. Protocol Limits for Yeasts/Molds?
22. Cleaning Validation for Homeopathic Drug Products
23. A Possible Approach for Biotech Limits
24. Establishing Clearance for Degraded Protein Actives
Visually Clean
25. Avoiding "Visually Dirty" Observations
26. What's a Visual Limit?
27. Visual Residue Limits - Part 1
28. Visual Residue Limits - Part 2
Analytical and Sampling Methods
29. Two More Nails in the Coffin?
30. More Swab Sampling Issues
31. Timing for Swab Sampling in a Protocol?
32. Pass/Fail Analytical Test Methods
Product Grouping
33. Issues in Product Grouping
34. Toxicity as a Worst-Case Grouping Factor
35. Another "Worst Case" Product Grouping Idea
Protocols and Procedures
36. Issues in Rinsing - Part 1
37. Issues in Rinsing - Part 2
38. Routine Monitoring for Highly Hazardous Products
39. "Concurrent Release" for Cleaning Validation
40. Dirty and Clean Hold Time Protocols
API Manufacture
41. A Critique of the APIC Guideline
42. Another Issue for API Synthesis
43. Contaminants in API Manufacture
Miscellaneous
44. Significant Figures: Back to Basics
45. The Value of a Protocol Worksheet for Manual Cleaning
46. Dealing with Used and New Equipment
47. Solving Cleaning Validation Problems by Analogy
48. Causing Cleaning Validation Problems by Analogy
Appendix A: Acronyms Used in this Volume
Appendix B: Shorthand Notations for Expressing Limits
Index
1. Use of the Term "Product"
2. Use of the Terms Grouping and Matrixing
3. Deviations and Nonconformances
4. Clarifying Terms: Blanks vs. Controls
5. Meaning of "Dedicated"?
6. Words (Again??)
Health-based Limits
7. What's at Stake with HBELs
8. A Look at the Revised Risk-MaPP
9. EMA's Q&A Clarification: Part 1
10. EMA's Q&A Clarification: Part 2
11. The EMA Q&A "Clarification" on Limits
12. The EMA Q&A on Routine Analytical Testing
13. Other Issues in EMA's Q&A
14. Highly Hazardous Products in Shared Facilities
Limits - General
15. EMA vs. ISPE on Cleaning Limits?
16. Does a High "Margin of Safety" Protect Patients?
17. What If the Next Product is the Same Product?
18. Limits for "Product A to Product A"
19. Surfaces Areas in Carryover Calculations
20. Carryover Calculation Errors to Avoid
21. Protocol Limits for Yeasts/Molds?
22. Cleaning Validation for Homeopathic Drug Products
23. A Possible Approach for Biotech Limits
24. Establishing Clearance for Degraded Protein Actives
Visually Clean
25. Avoiding "Visually Dirty" Observations
26. What's a Visual Limit?
27. Visual Residue Limits - Part 1
28. Visual Residue Limits - Part 2
Analytical and Sampling Methods
29. Two More Nails in the Coffin?
30. More Swab Sampling Issues
31. Timing for Swab Sampling in a Protocol?
32. Pass/Fail Analytical Test Methods
Product Grouping
33. Issues in Product Grouping
34. Toxicity as a Worst-Case Grouping Factor
35. Another "Worst Case" Product Grouping Idea
Protocols and Procedures
36. Issues in Rinsing - Part 1
37. Issues in Rinsing - Part 2
38. Routine Monitoring for Highly Hazardous Products
39. "Concurrent Release" for Cleaning Validation
40. Dirty and Clean Hold Time Protocols
API Manufacture
41. A Critique of the APIC Guideline
42. Another Issue for API Synthesis
43. Contaminants in API Manufacture
Miscellaneous
44. Significant Figures: Back to Basics
45. The Value of a Protocol Worksheet for Manual Cleaning
46. Dealing with Used and New Equipment
47. Solving Cleaning Validation Problems by Analogy
48. Causing Cleaning Validation Problems by Analogy
Appendix A: Acronyms Used in this Volume
Appendix B: Shorthand Notations for Expressing Limits
Index